X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
https://www.jnj.com/media-center/press-releases/u-s-fda-approves-edurant-ped-rilpivirine-for-certain-pediatric-patients-living-with-hiv-1
https://www.gsk.com/en-gb/media/press-releases/latitude-phase-iii-interim-trial-data-indicates-cabenuva-has-superior-efficacy-compared-to-daily-therapy/
https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-receives-approval-from-nmpa-for-vocabria-in-combination-with-rekambys/
https://www.ema.europa.eu/en/documents/overview/rekambys-epar-medicine-overview_en.pdf
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213120
https://www.prnewswire.com/news-releases/hagens-berman-sobol-shapiro-llp-hilliard--shadowen-llp-and-durie-tangri-llp-announce-a-class-action-involving-antiretroviral-drugs-301710696.html
https://www.fiercepharma.com/pharma/gileads-lenacapivir-approved-first-class-long-acting-hiv-injectable
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214058
https://www.jnj.com/u-s-fda-approves-cabenuva-cabotegravir-and-rilpivirine-for-adolescents-expanding-the-indication-of-the-first-and-only-complete-long-acting-injectable-hiv-regimen
https://endpts.com/with-competitors-circling-viiv-wins-another-label-update-for-long-acting-hiv-injectable-cabenuva/
https://viivhealthcare.com/en-gb/media/press-releases/2021/July/viiv-healthcare-study-shows-new-long-acting-hiv-regimen-cabenuva/
https://www.europeanpharmaceuticalreview.com/news/140642/fda-approves-first-extended-release-injectable-complete-regimen-for-hiv-cabenuva/
https://www.europeanpharmaceuticalreview.com/news/140642/fda-approves-first-extended-release-injectable-complete-regimen-for-hiv-cabenuva/
https://www.prnewswire.com/news-releases/janssen-announces-us-fda-approval-of-cabenuva-rilpivirine-and-cabotegravir-the-first-long-acting-regimen-for-the-treatment-of-hiv-301213000.html
http://www.pharmatimes.com/news/us_green_light_for_long-acting_hiv_regimen_cabenuva_1361756
http://www.pharmatimes.com/news/eu_authorises_first_long-acting_hiv_injectable_treatment_1360432
https://www.reuters.com/article/us-gsk-viiv-fda-resubmission/gsk-says-it-is-within-weeks-of-resubmitting-hiv-injection-cabenuva-idUSKBN24326Q
https://minakem.com/news/scientific-publication/minakem-announces-new-patent-for-a-new-process-of-preparation-of-rilpivirine/
https://www.fiercepharma.com/pharma/take-fda-gsk-s-viiv-scores-canadian-nod-for-once-monthly-hiv-regimen-cabenuva
https://www.biospectrumasia.com/news/39/14301/janssen-reports-positive-ph3-results-of-long-acting-injectable-hiv-treatment-regimen-.html
https://endpts.com/eight-weeks-between-each-hiv-treatment-gsk-notches-phiii-win-as-it-chases-ok-for-long-acting-regimen/
https://www.clinicaltrialsarena.com/news/viiv-long-acting-regimen-hiv/
http://www.pharmatimes.com/news/viiv_submits_regulatory_application_to_ema_for_investigational_hiv_combo_1295488
https://www.fiercepharma.com/pharma-asia/foreign-drugmakers-under-threat-as-china-rolls-out-drug-list-to-boost-generic
http://www.pharmatimes.com/news/viiv_submits_nda_for_first_long-acting,_injectable_hiv_combo_1286242
http://www.pharmatimes.com/news/positive_results_for_monthly_hiv_drug_1280938
https://www.fiercepharma.com/pharma/glaxosmithkline-s-viiv-touts-more-two-drug-hiv-success-double-ph3-win
https://seekingalpha.com/news/3411990-viiv-healthcares-hiv-med-juluca-okd-japan
https://www.reuters.com/article/us-gsk-hiv/long-lasting-hiv-injection-is-a-step-closer-after-second-gsk-study-idUSKCN1N42CP
https://www.fiercepharma.com/pharma/despite-tight-supply-gsk-s-shingrix-zooms-to-blockbuster-status
http://www.pharmatimes.com/news/encouraging_data_for_viivs_long-acting,_two-drug_hiv_therapy_1257551
https://www.ema.europa.eu/documents/overview/odefsey-epar-summary-public_en.pdf
http://www.pharmatimes.com/news/four_new_medicines_available_via_nhs_scotland_1251812
https://www.nasdaq.com/article/whats-in-the-cards-for-glaxo-gsk-this-earnings-season-cm995190
https://www.pharmacompass.com/pdf/news/viiv-healthcare-uk-receives-approval-in-europe-1527225820.pdf
https://www.raps.org/news-and-articles/news-articles/2018/3/ema%E2%80%99s-chmp-rejects-two-drugs-approved-by-us-fda-in
http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/03/news_detail_002925.jsp&mid=WC0b01ac058004d5c1
https://www.fiercepharma.com/marketing/fresh-off-its-juluca-approval-glaxosmithkline-beefs-up-trials-long-acting-hiv-duo
https://www.fiercepharma.com/pharma/glaxosmithkline-turns-up-heat-gilead-landmark-two-drug-hiv-win
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208452
http://www.pharmatimes.com/news/viivs_long-acting_two-drug_hiv_regimen_hits_targets_1199199
http://www.reuters.com/article/brief-gsk-says-viiv-healthcare-submits-idUSFWN1IY0TG
https://www.dddmag.com/news/2017/06/viiv-healthcare-files-regulatory-submissions-first-two-drug-hiv-maintenance-regimen
Market Place
Share 
